[go: up one dir, main page]

EA201791873A1 - Полиморф ингибиторов syk - Google Patents

Полиморф ингибиторов syk

Info

Publication number
EA201791873A1
EA201791873A1 EA201791873A EA201791873A EA201791873A1 EA 201791873 A1 EA201791873 A1 EA 201791873A1 EA 201791873 A EA201791873 A EA 201791873A EA 201791873 A EA201791873 A EA 201791873A EA 201791873 A1 EA201791873 A1 EA 201791873A1
Authority
EA
Eurasian Patent Office
Prior art keywords
polymorph
syk inhibitors
polymorphs
compound
formula
Prior art date
Application number
EA201791873A
Other languages
English (en)
Inventor
Питер Чи-чу Фун
Димитриос Стефанидис
Драгос Визитиу
Тим Г. Элфорд
Майкл Лерд Харри
Original Assignee
Джилид Коннектикут, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51301367&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201791873(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Джилид Коннектикут, Инк. filed Critical Джилид Коннектикут, Инк.
Publication of EA201791873A1 publication Critical patent/EA201791873A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Предложены полиморфы мезилата соединения формулы Iили его гидрата. Бисмезилат может также быть изображен как соединение формулы IAТакже в настоящем документе предложены композиции, содержащие указанные полиморфы, способы их получения и способы применения для указанных полиморфов.
EA201791873A 2013-07-30 2014-07-29 Полиморф ингибиторов syk EA201791873A1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361860197P 2013-07-30 2013-07-30

Publications (1)

Publication Number Publication Date
EA201791873A1 true EA201791873A1 (ru) 2018-09-28

Family

ID=51301367

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201690172A EA029281B1 (ru) 2013-07-30 2014-07-29 Полиморф ингибиторов syk
EA201791873A EA201791873A1 (ru) 2013-07-30 2014-07-29 Полиморф ингибиторов syk

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201690172A EA029281B1 (ru) 2013-07-30 2014-07-29 Полиморф ингибиторов syk

Country Status (32)

Country Link
US (4) US20160168155A1 (ru)
EP (1) EP3027618B1 (ru)
JP (1) JP6230709B2 (ru)
KR (1) KR101810798B1 (ru)
CN (1) CN105452252A (ru)
AP (1) AP2016009008A0 (ru)
AR (1) AR097158A1 (ru)
AU (2) AU2014296308C1 (ru)
CA (1) CA2919661C (ru)
CL (1) CL2016000238A1 (ru)
CR (1) CR20160098A (ru)
DK (1) DK3027618T3 (ru)
EA (2) EA029281B1 (ru)
ES (1) ES2822285T3 (ru)
HK (1) HK1222390A1 (ru)
HR (1) HRP20201582T1 (ru)
HU (1) HUE052090T2 (ru)
IL (1) IL243579A0 (ru)
MD (1) MD4659B1 (ru)
MX (1) MX2016001304A (ru)
MY (1) MY176803A (ru)
NZ (1) NZ715776A (ru)
PE (1) PE20160862A1 (ru)
PH (1) PH12016500169A1 (ru)
PL (1) PL3027618T3 (ru)
PT (1) PT3027618T (ru)
SG (1) SG11201600385TA (ru)
SI (1) SI3027618T1 (ru)
SV (1) SV2016005149A (ru)
TW (1) TW201602108A (ru)
UY (1) UY35683A (ru)
WO (1) WO2015017460A1 (ru)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3552607A3 (en) 2008-12-08 2020-01-15 Gilead Connecticut, Inc. Imidazopyrazine syk inhibitors
KR101717809B1 (ko) 2010-03-11 2017-03-17 질레드 코네티컷 인코포레이티드 이미다조피리딘 ｓｙｋ 억제제
HRP20201582T1 (hr) 2013-07-30 2021-02-19 Kronos Bio, Inc. Polimorf sik inhibitora
EA201690127A1 (ru) * 2013-07-30 2016-07-29 Джилид Коннектикут, Инк. Состав на основе ингибиторов syk
PT3076976T (pt) 2013-12-04 2020-12-07 Kronos Bio Inc Métodos para tratar cancros
US9290505B2 (en) 2013-12-23 2016-03-22 Gilead Sciences, Inc. Substituted imidazo[1,2-a]pyrazines as Syk inhibitors
UY35898A (es) 2013-12-23 2015-07-31 Gilead Sciences Inc ?compuestos inhibidores de syk y composiciones que los comprenden?.
KR20170029580A (ko) * 2014-07-14 2017-03-15 길리애드 사이언시즈, 인코포레이티드 암을 치료하기 위한 조합물
TW201639573A (zh) 2015-02-03 2016-11-16 吉李德科學股份有限公司 有關治療癌症之合併治療
US20160375019A1 (en) 2015-04-21 2016-12-29 Gilead Sciences, Inc. Treatment of chronic graft versus host disease with syk inhibitors
WO2017106564A1 (en) 2015-12-17 2017-06-22 Gilead Sciences, Inc. Combination of a jak inhibitor and a syk inhibitor for treating cancers and inflammatory disorders
US10472369B2 (en) * 2016-02-26 2019-11-12 Crystal Pharmatech Co., Ltd. Crystalline forms of (6-(1H-indazol-6-yl)-N-[4-(4-(4-morpholinyl)phenyl]imidazo[1,2-A]pyrazin-8-amine) methanesulfonate
AU2017325844A1 (en) 2016-09-14 2019-03-07 Gilead Sciences, Inc. SYK inhibitors
TW201822764A (zh) 2016-09-14 2018-07-01 美商基利科學股份有限公司 Syk抑制劑
JOP20180040A1 (ar) 2017-04-20 2019-01-30 Gilead Sciences Inc مثبطات pd-1/pd-l1
WO2018195471A1 (en) 2017-04-21 2018-10-25 Gilead Sciences, Inc. Syk inhibitors in combination with hypomethylating agents
CN115028640A (zh) 2017-08-25 2022-09-09 吉利德科学公司 Syk抑制剂的多晶型物
KR102708681B1 (ko) 2018-02-13 2024-09-26 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
WO2019204609A1 (en) 2018-04-19 2019-10-24 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
SI3793565T1 (sl) 2018-05-14 2022-04-29 Gilead Sciences, Inc. Inhibitorji MCL-1
EP3793998A1 (en) 2018-05-18 2021-03-24 Novartis AG Crystalline forms of a tlr7/tlr8 inhibitor
TWI809427B (zh) 2018-07-13 2023-07-21 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
AU2019366355B2 (en) 2018-10-24 2022-10-13 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
MX2021010131A (es) 2019-02-22 2021-11-18 Kronos Bio Inc Formas sólidas de pirazinas condensadas a manera de inhibidores de syk.
CN113402506B (zh) * 2021-06-17 2023-06-16 四川大学 中间体和制备方法及其在合成长春布宁上的应用

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2607813B1 (fr) 1986-12-05 1989-03-31 Montpellier I Universite Alkylamino-8 imidazo (1,2-a) pyrazines et derives, leur preparation et leur application en therapeutique
US5137876A (en) 1990-10-12 1992-08-11 Merck & Co., Inc. Nucleoside antiviral and anti-inflammatory compounds and compositions and methods for using same
DE4327027A1 (de) 1993-02-15 1994-08-18 Bayer Ag Imidazoazine
DE4337611A1 (de) 1993-11-04 1995-05-11 Boehringer Ingelheim Kg Neue Benzoylguanidine, ihre Herstellung und ihre Verwendung in Arzneimitteln
DE4337609A1 (de) 1993-11-04 1995-05-11 Boehringer Ingelheim Kg Neue Pyrazincarboxamidderivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
FR2711993B1 (fr) 1993-11-05 1995-12-01 Rhone Poulenc Rorer Sa Médicaments contenant des dérivés de 7H-imidazol[1,2-a]pyrazine-8-one, les nouveaux composés et leur préparation.
JP3696884B2 (ja) 1994-03-25 2005-09-21 アイソテクニカ、インコーポレーテッド ジュウテリウム化による薬物の効能の増強
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
FR2723373B1 (fr) 1994-08-02 1996-09-13 Rhone Poulenc Rorer Sa Forme purifiee de streptogramines, sa preparation et les compositions pharmaceutiques qui la contiennent
WO1996034866A1 (en) 1995-05-01 1996-11-07 Fujisawa Pharmaceutical Co., Ltd. Imidazo 1,2-a pyridine and imidazo 1,2-a pyridezine derivatives and their use as bone resorption inhibitors
US5593997A (en) 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
SE9704404D0 (sv) 1997-11-28 1997-11-28 Astra Ab New compounds
DE19948434A1 (de) 1999-10-08 2001-06-07 Gruenenthal Gmbh Substanzbibliothek enthaltend bicyclische Imidazo-5-amine und/oder bicyclische Imidazo-3-amine
JP2001302667A (ja) 2000-04-28 2001-10-31 Bayer Ag イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
GB0018473D0 (en) 2000-07-27 2000-09-13 Merck Sharp & Dohme Therapeutic agents
DE10050663A1 (de) 2000-10-13 2002-04-18 Gruenenthal Gmbh Verwendung von substituierten Imidazo[1,2-a]pyridin-, -pyrimidin- und pyrazin-3-yl-amin-Derivaten zur Herstellung von Medikamenten zur NOS-Inhibierung
EP1363702A4 (en) 2001-01-30 2007-08-22 Cytopia Pty Ltd PROCESS FOR INHIBITING KINASES
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
WO2002076985A1 (en) 2001-03-23 2002-10-03 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
BR0307735A (pt) 2002-02-19 2005-01-25 Upjohn Co Carboxamidas heteroaromáticas com ligação-n em ponte biciclìcas fundidas para o tratamento de doença
CN100537571C (zh) 2002-04-19 2009-09-09 细胞基因组公司 咪唑并[1,2-а]吡嗪-8-基胺,其制备方法及使用方法
DE60326341D1 (de) 2002-05-14 2009-04-09 Xenova Ltd Verfahren zur herstellung von anthranilsäurederivat-hydrat
WO2004022562A1 (en) 2002-09-09 2004-03-18 Cellular Genomics, Inc. 6-ARYL-IMIDAZO[1,2-a]PYRAZIN-8-YLAMINES, METHOD OF MAKING, AND METHOD OF USE THEREOF
DE60317529T2 (de) 2002-09-19 2008-09-25 Schering Corp. Imidazopyridine als hemmstoffe cyclin abhängiger kinasen
CN1694706A (zh) 2002-09-23 2005-11-09 先灵公司 用作依赖细胞周期蛋白的激酶抑制剂的新的咪唑并吡嗪
NZ538685A (en) 2002-09-23 2008-02-29 Schering Corp Imidazopyrazines as cyclin dependent kinase inhibitors
US7160885B2 (en) 2003-02-10 2007-01-09 Cgi Pharmaceuticals, Inc. Certain 6, 8-(heteroaryl or aryl) disubstituted imidazo[1,2-a]pyrazines as modulators of Hsp90 complex activity
US7186832B2 (en) 2003-02-20 2007-03-06 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
US7157460B2 (en) 2003-02-20 2007-01-02 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
US20060183746A1 (en) 2003-06-04 2006-08-17 Currie Kevin S Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
WO2005014599A1 (en) 2003-06-04 2005-02-17 Cellular Genomics, Inc. Imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton’s tyrosine kinase by such compounds
US7393848B2 (en) 2003-06-30 2008-07-01 Cgi Pharmaceuticals, Inc. Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of Bruton's tyrosine kinase by such compounds
US7259164B2 (en) 2003-08-11 2007-08-21 Cgi Pharmaceuticals, Inc. Certain substituted imidazo[1,2-a]pyrazines, as modulators of kinase activity
WO2005047290A2 (en) 2003-11-11 2005-05-26 Cellular Genomics Inc. Imidazo[1,2-a] pyrazin-8-ylamines as kinase inhibitors
US7973161B2 (en) 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
WO2005085252A1 (en) 2004-03-04 2005-09-15 Biofocus Discovery Limited Imidazo ‘1,2-a’ pyrazine compounds which interact with protein kinases
JP2008516973A (ja) 2004-10-15 2008-05-22 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
SG159549A1 (en) 2004-11-10 2010-03-30 Cgi Pharmaceuticals Inc Imidazo[1,2-a] pyrazin-8-ylamines useful as modulators of kinase activity
PT1888550E (pt) 2005-05-12 2014-09-03 Abbvie Bahamas Ltd Promotores de apoptose
BRPI0618520A2 (pt) 2005-11-10 2011-09-06 Schering Corp imidazopirazinas como inibidores de proteìna cinase
ES2549862T3 (es) 2006-08-30 2015-11-02 Cellzome Limited Derivados de triazol como inhibidores de quinasa
PE20080839A1 (es) 2006-09-11 2008-08-23 Cgi Pharmaceuticals Inc Determinadas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas
CL2008002793A1 (es) 2007-09-20 2009-09-04 Cgi Pharmaceuticals Inc Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras
WO2009070639A1 (en) 2007-11-28 2009-06-04 Irx Therapeutics, Inc. Method of increasing immunological effect
CN101952283B (zh) 2007-12-14 2013-04-17 霍夫曼-拉罗奇有限公司 咪唑并[1，2-a]吡啶和咪唑并[1，2-b]哒嗪衍生物
NZ587039A (en) 2008-02-13 2013-01-25 Gilead Connecticut Inc 6-aryl-imidazo[1, 2-a]pyrazine derivatives, method of making, and method of use thereof
CN102014910A (zh) 2008-03-07 2011-04-13 美国辉瑞有限公司 在无食物条件下施用齐拉西酮的方法、剂型和试剂盒
ES2552320T3 (es) 2008-06-24 2015-11-27 F. Hoffmann-La Roche Ag Nuevas piridín-2-onas y piridazín-3-onas sustituidas
CN102083819B (zh) 2008-07-02 2014-07-09 霍夫曼-拉罗奇有限公司 作为激酶抑制剂的新型苯基吡嗪酮
CA2726460C (en) 2008-07-15 2017-02-21 F. Hoffmann-La Roche Ag Novel phenyl-imidazopyridines and pyridazines
TWI453207B (zh) 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶，其組合物及使用其之治療方法
US8455493B2 (en) * 2008-12-08 2013-06-04 Gilead Connecticut, Inc. Imidazopyrazine Syk inhibitors
US8450321B2 (en) 2008-12-08 2013-05-28 Gilead Connecticut, Inc. 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor
EP3552607A3 (en) 2008-12-08 2020-01-15 Gilead Connecticut, Inc. Imidazopyrazine syk inhibitors
US8362013B2 (en) 2009-04-30 2013-01-29 Abbvie Inc. Salt of ABT-263 and solid-state forms thereof
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
JP5714600B2 (ja) 2009-12-18 2015-05-07 フリースランドカンピナ・ネーデルランド・ホールディング・ビー．ブイ．ＦｒｉｅｓｌａｎｄＣａｍｐｉｎａ Ｎｅｄｅｒｌａｎｄ Ｈｏｌｄｉｎｇ Ｂ．Ｖ． 共加工された錠用賦形剤混合物、その調製及び使用
KR101717809B1 (ko) 2010-03-11 2017-03-17 질레드 코네티컷 인코포레이티드 이미다조피리딘 ｓｙｋ 억제제
RS56697B1 (sr) 2010-11-23 2018-03-30 Abbvie Inc Soli i kristalni oblici agensa za indukciju apoptoze
JPWO2012147832A1 (ja) * 2011-04-27 2014-07-28 第一三共株式会社 フェニルピロール誘導体の結晶
WO2013188856A1 (en) 2012-06-14 2013-12-19 Gilead Connecticut, Inc. Imidazopyrazine syk inhibitors
CA2882134A1 (en) 2012-08-14 2014-02-20 Gilead Calistoga Llc Combination therapies for treating cancer
US20140148430A1 (en) 2012-11-26 2014-05-29 Gilead Connecticut, Inc. Imidazopyridines syk inhibitors
HRP20201582T1 (hr) 2013-07-30 2021-02-19 Kronos Bio, Inc. Polimorf sik inhibitora
EA201690127A1 (ru) * 2013-07-30 2016-07-29 Джилид Коннектикут, Инк. Состав на основе ингибиторов syk
ES2656192T3 (es) 2013-07-31 2018-02-26 Gilead Sciences, Inc. Inhibidores de SKY
PT3076976T (pt) 2013-12-04 2020-12-07 Kronos Bio Inc Métodos para tratar cancros
JP6425727B2 (ja) 2013-12-23 2018-11-21 ギリアード サイエンシーズ， インコーポレイテッド 大環状ｈｃｖ ｎｓ３阻害トリペプチド
US9290505B2 (en) 2013-12-23 2016-03-22 Gilead Sciences, Inc. Substituted imidazo[1,2-a]pyrazines as Syk inhibitors
UY35898A (es) 2013-12-23 2015-07-31 Gilead Sciences Inc ?compuestos inhibidores de syk y composiciones que los comprenden?.
KR20170029580A (ko) 2014-07-14 2017-03-15 길리애드 사이언시즈, 인코포레이티드 암을 치료하기 위한 조합물
TW201617074A (zh) 2014-07-14 2016-05-16 吉李德科學股份有限公司 Ｓｙｋ（脾酪胺酸激酶）抑制劑
TW201639573A (zh) * 2015-02-03 2016-11-16 吉李德科學股份有限公司 有關治療癌症之合併治療
US20160375019A1 (en) 2015-04-21 2016-12-29 Gilead Sciences, Inc. Treatment of chronic graft versus host disease with syk inhibitors

Also Published As

Publication number Publication date
MX2016001304A (es) 2016-04-07
AU2014296308C1 (en) 2018-09-13
DK3027618T3 (da) 2020-10-12
HRP20201582T1 (hr) 2021-02-19
PH12016500169A1 (en) 2016-04-25
JP2016527268A (ja) 2016-09-08
AP2016009008A0 (en) 2016-01-31
MD20160017A2 (ru) 2016-08-31
MD4659B1 (ru) 2019-11-30
TW201602108A (zh) 2016-01-16
SG11201600385TA (en) 2016-02-26
KR101810798B1 (ko) 2017-12-19
HK1222390A1 (zh) 2017-06-30
US20180099971A1 (en) 2018-04-12
SI3027618T1 (sl) 2021-01-29
SV2016005149A (es) 2017-04-03
KR20160038007A (ko) 2016-04-06
EP3027618B1 (en) 2020-07-08
PL3027618T3 (pl) 2021-04-19
NZ715776A (en) 2017-04-28
PT3027618T (pt) 2020-10-12
CA2919661C (en) 2020-08-18
JP6230709B2 (ja) 2017-11-15
EA029281B1 (ru) 2018-03-30
EA201690172A1 (ru) 2016-07-29
US10266539B2 (en) 2019-04-23
US20150038505A1 (en) 2015-02-05
CL2016000238A1 (es) 2016-07-22
CA2919661A1 (en) 2015-02-05
CN105452252A (zh) 2016-03-30
CR20160098A (es) 2016-07-11
ES2822285T3 (es) 2021-04-30
PE20160862A1 (es) 2016-09-24
MY176803A (en) 2020-08-21
US9657023B2 (en) 2017-05-23
US20170217967A1 (en) 2017-08-03
EP3027618A1 (en) 2016-06-08
US20160168155A1 (en) 2016-06-16
UY35683A (es) 2015-02-27
AU2014296308A1 (en) 2016-02-04
AU2014296308B2 (en) 2017-06-08
AU2017225136A1 (en) 2017-10-05
AR097158A1 (es) 2016-02-24
IL243579A0 (en) 2016-02-29
WO2015017460A1 (en) 2015-02-05
HUE052090T2 (hu) 2021-04-28

Similar Documents

Publication Publication Date Title
EA201791873A1 (ru) Полиморф ингибиторов syk
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
EA201692219A1 (ru) Способы получения противовирусных соединений
PH12017500408A1 (en) Heteroaryl compunds as btk inhibitors and uses thereof
EA201401054A1 (ru) N-циклиламиды в качестве нематоцидов
EA201790395A1 (ru) Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы
SI3066085T1 (sl) Postopek sinteze inhibitorja indolamina 2,3-dioksigenaze
PH12015502031B1 (en) Tetrahydropyrrolothiazine compounds
EA201591634A1 (ru) Дигидропиридопиримидиновые соединения
MD20160106A2 (ru) Бициклические конденсированные арильные или гетероарильные соединения и их применение в качестве ингибиторов IRAK4
ZA201503333B (en) Compounds useful as inhibitors of indoleamine 2,3-dioxygenase
EA201690473A1 (ru) Комбинированный состав двух противовирусных соединений
EA201590552A1 (ru) Аминохинолины в качестве ингибиторов киназы
MX2015017156A (es) Inhibidores de bace.
EA201500931A1 (ru) Производные пиридин-4-ила
CY1118079T1 (el) Μεθοδος παρασκευης του αλατος l-αργινινικης περινδοπριλης
EA201591915A1 (ru) Соединения феноксиэтил дигидро-1h-изохинолина
UA113086C2 (xx) Піразольні сполуки як інгібітори sglt1
DOP2019000021A (es) Derivado de triazolopirazinona útil como un inhibidor de pde1 humana
EA201491227A1 (ru) Новые производные морфолинила, подходящие для применения в качестве ингибиторов mogat-2
EA201591498A1 (ru) Азетидинилоксифенилпирролидиновые соединения
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
CY1121116T1 (el) Νεα μεθοδος για την συνθεση αγομελατινης
EA201690294A1 (ru) Новые соединения и их применение для получения tau-визуализирующих агентов и tau-визуализирующих составов
EA201690908A1 (ru) Пиразолопиримидиновые соединения